A single dose of a CCR5/CD3 bispecific antibody depleted the SIV reservoir in infant macaques and showed durable aviraemia after antiretroviral therapy was stopped. The reported effect suggests the antibody may overcome reservoir persistence by engaging T cells through a dual-receptor mechanism. The study describes a clear translational milestone: reservoir reduction plus apparent viral clearance following ART interruption, an outcome that has been difficult to reproduce with conventional approaches. The work strengthens the rationale for targeting CCR5 and CD3 simultaneously to drive immune-mediated elimination of infected cells. While the findings are preclinical and disease-specific to SIV, the model supports further evaluation of similar bispecific strategies in broader primate settings and with careful safety monitoring. For HIV cure research, the study contributes to the evidence base supporting “shock and kill” alternatives, focusing instead on immune recruitment and targeted killing at the reservoir interface.